The chlorofluorocarbon (CFC)based metered dose inhaler, which has been the
mainstay of the management of obstructive lung diseases, will soon be phase
d out world wide and replaced by CFC-free devices. Patients will have to be
changed to the devices in a co-ordinated manner to avoid any risk to their
health and safety. The different shapes and aerosol delivery characteristi
cs of the new inhalers, as well as their distinctive taste, could add to th
e levels of poor drug use already experienced in asthma. From previous chan
ge scenarios in disease management, the potential for unstable asthma contr
ol is a real possibility with all the attendant costs. By using the time av
ailable before CFC-based inhalers are withdrawn, there is an opportunity to
enhance asthma management during this period of change.